Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Significant Growth in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 229,146 shares, a growth of 1,343.5% from the September 30th total of 15,874 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 954,798 shares, the days-to-cover ratio is currently 0.2 days.

Oncotelic Therapeutics Trading Down 3.6%

Shares of Oncotelic Therapeutics stock opened at $0.02 on Tuesday. Oncotelic Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.11. The stock has a market cap of $7.44 million, a P/E ratio of 0.03 and a beta of -0.18. The company has a quick ratio of 0.08, a current ratio of 0.08 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $0.03 and its 200-day moving average is $0.04.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc is a biotechnology company focused on developing therapeutics for cancer and other serious diseases. Its research platform centers on RNA-based medicines, including antisense oligonucleotides designed to regulate disease-related genetic signals and immune responses.

The company’s leading investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide intended to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has evaluated OT-101 in oncology indications including glioblastoma, pancreatic cancer and melanoma, although the product remains investigational and is not approved as a commercial treatment.

Oncotelic was formerly known as Mateon Therapeutics and adopted its current name as it refined its focus on oncology and related therapeutic programs.